Drug Trial Radar · NCT00561470
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Last checked: Nov 20, 2026Latest source record: Sep 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,226
Actual
Start
Nov 2007
Primary completion
Feb 2011
Study completion Jun 2012
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals; NSABP Foundation Inc
- First posted
- Nov 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease. The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.
Conditions
- Colorectal Neoplasms
- Neoplasm Metastasis
Interventions
PlaceboDrug
4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)Drug
4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)Drug
The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)Drug
The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
Locations
221 sites in 28 countries. Site status is shown where the registry gives one.
Sanofi-Aventis Investigational Site Number 840119
Birmingham, Alabama
Sanofi-Aventis Investigational Site Number 840074
Muscle Shoals, Alabama
Sanofi-Aventis Investigational Site Number 840093
Hot Springs, Arizona
Sanofi-Aventis Investigational Site Number 840080
Anaheim, California
Sanofi-Aventis Investigational Site Number 840076
Fountain Valley, California
Sanofi-Aventis Investigational Site Number 840120
Fountain Valley, California
Sanofi-Aventis Investigational Site Number 840073
Greenbrae, California
Sanofi-Aventis Investigational Site Number 840101
Hayward, California
Sanofi-Aventis Investigational Site Number 840046
La Jolla, California
Sanofi-Aventis Investigational Site Number 840116
Loma Linda, California
Sanofi-Aventis Investigational Site Number 840048
Long Beach, California
Sanofi-Aventis Investigational Site Number 840201
Oakland, California
Sanofi-Aventis Investigational Site Number 840901
Roseville, California
Sanofi-Aventis Investigational Site Number 840042
Sacramento, California
Sanofi-Aventis Investigational Site Number 840301
Sacramento, California
Sanofi-Aventis Investigational Site Number 840112
Salinas, California
Sanofi-Aventis Investigational Site Number 840006
San Diego, California
Sanofi-Aventis Investigational Site Number 840106
San Diego, California
Sanofi-Aventis Investigational Site Number 840206
San Diego, California
Sanofi-Aventis Investigational Site Number 840306
San Diego, California
Sanofi-Aventis Investigational Site Number 840406
San Diego, California
Sanofi-Aventis Investigational Site Number 840506
San Diego, California
Sanofi-Aventis Investigational Site Number 840606
San Diego, California
Sanofi-Aventis Investigational Site Number 840706
San Diego, California
Sanofi-Aventis Investigational Site Number 840806
San Diego, California
Sanofi-Aventis Investigational Site Number 840906
San Diego, California
Sanofi-Aventis Investigational Site Number 840401
San Francisco, California
Sanofi-Aventis Investigational Site Number 840601
San Jose, California
Sanofi-Aventis Investigational Site Number 840501
Santa Clara, California
Sanofi-Aventis Investigational Site Number 840801
South San Francisco, California
Sanofi-Aventis Investigational Site Number 840001
Vallejo, California
Sanofi-Aventis Investigational Site Number 840701
Walnut Creek, California
Sanofi-Aventis Investigational Site Number 840071
Stamford, Connecticut
Sanofi-Aventis Investigational Site Number 840014
Newark, Delaware
Sanofi-Aventis Investigational Site Number 840089
Boynton Beach, Florida
Sanofi-Aventis Investigational Site Number 840041
Gainesville, Florida
Sanofi-Aventis Investigational Site Number 840031
Gainesville, Florida
Sanofi-Aventis Investigational Site Number 840122
Miami, Florida
Sanofi-Aventis Investigational Site Number 840079
The Villages, Florida
Sanofi-Aventis Investigational Site Number 840087
Chicago, Illinois
Showing 40 of 221 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.